A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.